Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Downgraded by Wall Street Zen to Buy

Wall Street Zen downgraded shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) from a strong-buy rating to a buy rating in a research note issued to investors on Saturday morning.

FMS has been the subject of several other research reports. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, January 27th. Weiss Ratings cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, March 13th. Erste Group Bank lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Jefferies Financial Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a research note on Tuesday, February 24th. Finally, Truist Financial set a $28.00 price target on Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. Five equities research analysts have rated the stock with a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $28.00.

Fresenius Medical Care AG & Co. KGaA Stock Up 0.2%

Shares of NYSE FMS opened at $22.45 on Friday. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $20.94 and a 1 year high of $30.46. The company has a market capitalization of $12.54 billion, a price-to-earnings ratio of 11.75, a price-to-earnings-growth ratio of 2.12 and a beta of 0.89. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.26 and a quick ratio of 0.92. The business has a 50-day moving average of $23.09 and a two-hundred day moving average of $24.02.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its earnings results on Saturday, February 14th. The company reported $1.69 earnings per share for the quarter. The business had revenue of $5.95 billion for the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.73% and a net margin of 5.03%. On average, analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Morgan Stanley boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 47.2% in the 4th quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock valued at $70,027,000 after purchasing an additional 942,497 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 279.7% during the 2nd quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock worth $9,637,000 after buying an additional 248,477 shares in the last quarter. ABC Arbitrage SA lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 1,136.0% in the 4th quarter. ABC Arbitrage SA now owns 249,800 shares of the company’s stock valued at $5,950,000 after buying an additional 229,589 shares during the period. Integral Health Asset Management LLC lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 44.4% in the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock valued at $15,483,000 after buying an additional 200,000 shares during the period. Finally, Pzena Investment Management LLC boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 1.0% in the third quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock valued at $390,128,000 after buying an additional 153,870 shares in the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.